[1] |
ZENG Lijie, WANG Liang, YANG Lei .
Clinical features and treatment efficacy analysis of central nervous system involvement in extranodal nasal-type natural killer/T-cell lymphoma
[J]. Chinese Journal of Oncology Prevention and Treatment, 2025, 17(1): 81-87.
|
[2] |
GUO Zhiyu, CAO Tianyu, WANG Weidong, GUO Xingxian, MA Wanqi, LU Yuanyuan, ZHAO Xiaodi, JI Gang.
Correlation between blood lipid levels and survival prognosis of gastric cancer patients under operation: A retrospective cohort study
[J]. Chinese Journal of Oncology Prevention and Treatment, 2024, 16(6): 687-693.
|
[3] |
GAO Fangfang, CHEN Binjie, TAN Qixing, HUANG Zhen, LU Weifeng, WEI Changyuan.
Analysis of risk factors of prognosis,recurrence and metastasis of breast cancer patients with non-pathologic complete response after neoadjuvant chemotherapy
[J]. Chinese Journal of Oncology Prevention and Treatment, 2023, 15(6): 650-656.
|
[4] |
ZHU Lei, LEI Yi, MO Ligen, LING Guoyuan, DENG Teng, HUANG Qianrong, JIANG Qian, SHI Liu.
Application of neuronavigation combined with fluorescein sodium in intraoperative imaging-assisted resection of brain metastases
[J]. Chinese Journal of Oncology Prevention and Treatment, 2023, 15(6): 657-662.
|
[5] |
WU Lili, ZHU Yingli, ZHUO Xiaolu, HUANG Lina, YE Dong.
Comparison of clinical efficacy of icotinib and gefitinib in the treatment of EGFR⁃mutated advanced lung adenocarcinoma
[J]. Chinese Journal of Oncology Prevention and Treatment, 2022, 14(6): 642-646.
|
[6] |
LIANG Xi, LING Guoyuan, DENG Teng, MO Ligen.
Clinical study of intraoperative contrast⁃assisted resection of glioma with low⁃dose sodium fluorescein
[J]. Chinese Journal of Oncology Prevention and Treatment, 2022, 14(6): 647-652.
|
[7] |
LUO Xixi, CHEN Jiamei, SHI Wei, CHEN Yongshun.
Efficacy and safety of Regorafenib combined with PD⁃1 inhibitors in advanced microsatellite stable colorectal carcinoma
[J]. Chinese Journal of Oncology Prevention and Treatment, 2022, 14(5): 521-528.
|
[8] |
CHEN Xiaolei, ZHANG Yong, ZHANG Yue, LI Jie, ZHOU Hebing .
Retrospective analysis of efficacy and prognosis of newly diagnosed multiple myeloma patients with 1q21 amplification
[J]. Chinese Journal of Oncology Prevention and Treatment, 2022, 14(5): 541-547.
|
[9] |
DENG Yang, WANG Yuan, BAO Shengxue, LIU Zhilin, DING Guanghong, HAO Langsong.
Effect of electroacupuncture and medicine combination on gastrointestinal function in patients with colorectal cancer after laparoscopic surgery based on the concept of enhanced recovery after surgery
[J]. Chinese Journal of Oncology Prevention and Treatment, 2022, 14(2): 194-198.
|
[10] |
LI Xiajin, LUO Ningbin, CHEN Miao, SU Danke.
Predictive value of preoperative CT signs combined with α?fetoprotein in early recurrence of solitary hepatocellular carcinoma
[J]. Chinese Journal of Oncology Prevention and Treatment, 2022, 14(2): 203-207.
|
[11] |
LIU Fuhong, XUE Song, ZHANG Yongping, HUANG Wenqiu, WANG Jingbo.
Allogeneic hematopoietic stem cell transplantation for T cell acute lymphoblastic leukemia and lymphoma: a clinical report of 50 cases
[J]. Chinese Journal of Oncology Prevention and Treatment, 2022, 14(1): 81-86.
|
[12] |
WANG Zimeng, XIANG Zuolin.
Clinical efficacy of stereotactic body radiation therapy on liver metastases
[J]. Chinese Journal of Oncology Prevention and Treatment, 2021, 13(6): 641-646.
|
[13] |
GUO Dezhen, HUANG Ao, ZHANG Shiyu, CHENG Jianwen, WANG Yupeng, YAN Jiayan, HUANG Xiaowu, FAN Jia, YANG Xinrong, ZHOU Jian.
Feasibility study of short tandem repeat genotyping to identify the origin of ultra?late recurrence of liver cancer after liver transplantation
[J]. Chinese Journal of Oncology Prevention and Treatment, 2021, 13(5): 458-463.
|
[14] |
ZHOU Yongxing, TAN Guanqiao, ZHOU Dawei.
Construction and application of an early recurrence prediction model for pancreatic head cancer after radical pancreaticoduodenectomy
[J]. Chinese Journal of Oncology Prevention and Treatment, 2021, 13(5): 523-528.
|
[15] |
YANG Guangzhong, GENG Chuanying, WU Yin, LIU Aijun, LENG Yun, LI Yanchen, GAO Wen, CHEN Wenming.
Clinical efficacy of domestic bortezomib (Xintai) in the treatment of multiple myeloma and its safety
[J]. Chinese Journal of Oncology Prevention and Treatment, 2021, 13(4): 385-388.
|